The new approval is a boost for Sanofi because the VRd regimen has become the preferred first-line treatment option for transplant-ineligible multiple myeloma patients in recent years, giving ...

Sanofi’s anti-CD38 antibody Sarclisa has struggled to make headway against Genmab and Johnson & Johnson’s rival Darzalex since it was first approved for multiple myeloma, but new data from the ...

Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in combination with ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Drugmakers had hoped that inhibiting receptor-interacting protein kinase would decrease inflammation and reduce neuronal degeneration in patients with multiple sclerosis and other neurodegenerative co ...

including rare cancers such as multiple myeloma, acute myeloid leukemia, and certain types of lymphomas, as well as gastrointestinal and lung cancers. Sanofi and Orano Med are members of the Paris ...

RIO DE JANEIRO — A quadruplet induction regimen of isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in the treatment of newly diagnosed multiple myeloma (MM) shows a notably ...

Sanofi is deepening its commitment to targeted ... including rare cancers such as multiple myeloma, acute myeloid leukemia, and certain types of lymphomas. The scope of the research will also ...

including rare cancers such as multiple myeloma, acute myeloid leukemia, and certain types of lymphomas, as well as gastrointestinal and lung cancers. Sanofi and Orano Med are members of the Paris ...

Paris, October 17, 2024. Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine ...